NSEGeneral Updates6d ago · 14 Oct 2026, 02:01 pm
General Updates
Sakar Healthcare Limited · SAKAR
✦ AI Summary▲ PositiveExpansion
Sakar Healthcare Limited has expanded its global export model with oncology products, receiving approvals in various regions and starting commercial supplies.
Analysis Scores
Earnings Impact8/10
Growth Catalyst9/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact9/10
Market Sentiment9/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Sakar Healthcare Limited has informed the Exchange about Sakar s global export model expands with oncology products
Attachments (1)
📄pdf
Download →
SAKAR_14102026140052_Announcement.pdf
View document text
Certified ISO 9001 :2015 by Sakar
Healthcare Limited
Corporate Office :
Date: October 14,2026 406, Silver Oaks Comm. Complex,
Opp. Arun Society, Paldi,
Ahmedabad-380 007. Gujarat, India.
Phone : 079-26584655
The Manager CIN No. : L24231 GJ2004PLC043861
Listing Compliance Department E-mail: info@sakarhealthcare.com
Web : www.sakarhealthcare.com
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai-400051, India
SYMBOL: SAKAR
SUB: Sakar's global export model expands with oncology products
Dear All,
Sakar Healthcare Ltd. emerges with the oncology portfolio across geographies. Be it the
approvals in form of Marketing Authorisation (MA), addition of site under variations or
participating in global events like Cl'Hl, worldwide, Sakar has initiated its' foot prints globally.
The salient progress has been noted with
• In-house prepared product dossiers are getting approvals covering EU, the UK, APAC,
Canada and LatAm regions- with 22being granted MAs of 190 submitted to various reguJatory
bodies worldwide
• Till date 1I-site variations got approval at stringent markets which includes MNCs like
Accord Healthcare Ltd, Tillomed Laboratories Ltd, Heumann Pharma GmbH & Co. Generica
•2 of7 applied for CEPs (21 in-house developed APls) have been approved as on date, which
encouraged to proceed with vertical integration of the unit
• Commercial supplies have started catering to such approvals from Sakar's research-driven
API-integrated EU GMP approved oncology FDF manufacturing site
Presently Sakar's business is majorly skewed towards the export of the oncology products.
Therefore, the proposed capping on MRP for oncology products in domestic market doesn't
impact business at Sakar, as the directive states "Since the move only regulates the trade
margin, manufacturers' selling prices and revenues will not be affected, the officials explained"
(ref: ET, October 12,2026).
The encouragement and guidance from you all have always helped in our endeavour to proceed
and reach newer heights.
Thank you.
Yours faithfully,
Regd. Office / Works: Block No.1 0-13, Sarkhej-Bavla Road, Village Changodar, Dist. Ahmedabad - 382 213. India.
Phone: +91 99091 53977